Figure 3.3 Hazard ratio of 1-year clinically driven target vessel revascularization in

Multivariate Cox proportional hazards analysis identified sirolimus-eluting stent utilization to be independently associated with a reduced risk of adverse clinical events (Table 3.4). After adjustment for other independent variables, SES significantly decreased the risk of clinically driven target vessel revascularization (adjusted HR 0.33 [95% CI 0.20-0.56]; p<0.01) and the risk of major adverse cardiac events (adjusted HR 0.55 [95% CI 0.38-0.80]; p<0.01).